231 related articles for article (PubMed ID: 35735450)
1. Immunotherapy as a Neoadjuvant Therapy for a Patient with Hepatocellular Carcinoma in the Pretransplant Setting: A Case Report.
Abdelrahim M; Esmail A; Umoru G; Westhart K; Abudayyeh A; Saharia A; Ghobrial RM
Curr Oncol; 2022 Jun; 29(6):4267-4273. PubMed ID: 35735450
[TBL] [Abstract][Full Text] [Related]
2. Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma.
Whitham Z; Hsiehchen D
Surg Oncol Clin N Am; 2024 Jan; 33(1):87-97. PubMed ID: 37945147
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant systemic therapy for hepatocellular carcinoma.
Chick RC; Ruff SM; Pawlik TM
Front Immunol; 2024; 15():1355812. PubMed ID: 38495884
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Immune Checkpoint Inhibitors in hepatocellular carcinoma: a meta-analysis and systematic review.
Tian C; Yu Y; Wang Y; Yang L; Tang Y; Yu C; Feng G; Zheng D; Wang X
Front Immunol; 2024; 15():1352873. PubMed ID: 38440727
[TBL] [Abstract][Full Text] [Related]
8. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
Kim Y; Stahl CC; Makramalla A; Olowokure OO; Ristagno RL; Dhar VK; Schoech MR; Chadalavada S; Latif T; Kharofa J; Bari K; Shah SA
Surgery; 2017 Dec; 162(6):1250-1258. PubMed ID: 29033224
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study.
Woei-A-Jin FJSH; Weijl NI; Burgmans MC; Fariña Sarasqueta A; van Wezel JT; Wasser MNJM; Coenraad MJ; Burggraaf J; Osanto S
Oncologist; 2021 Oct; 26(10):854-864. PubMed ID: 34251745
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapies in resectable hepatocellular carcinoma: Exploring strategies to improve prognosis.
Ma YN; Jiang X; Song P; Tang W
Biosci Trends; 2024 Mar; 18(1):21-41. PubMed ID: 38382930
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy and transplantation for hepatocellular carcinoma.
Tabrizian P; Abdelrahim M; Schwartz M
J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
[TBL] [Abstract][Full Text] [Related]
13. Does neoadjuvant doxorubicin drug-eluting bead transarterial chemoembolization improve survival in patients undergoing liver transplant for hepatocellular carcinoma?
Dorcaratto D; Udupa V; Hogan NM; Brophy DP; McCann JW; Maguire D; Geoghegan J; Cantwell CP; Hoti E
Diagn Interv Radiol; 2017; 23(6):441-447. PubMed ID: 29063856
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
[TBL] [Abstract][Full Text] [Related]
15. Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma.
Takamoto T; Maruki Y; Kondo S
Expert Opin Pharmacother; 2023; 24(14):1567-1575. PubMed ID: 37357809
[TBL] [Abstract][Full Text] [Related]
16. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
[TBL] [Abstract][Full Text] [Related]
17. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
18. Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates.
Castroagudín JF; Delgado M; Villanueva A; Bustamante M; Martínez J; Otero E; Tomé S; Martínez SM; Segade FR; Conde R; Dominguez-Muñoz E; Varo E
Transplant Proc; 2005 Nov; 37(9):3871-3. PubMed ID: 16386568
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma.
Baigi T; Brown EN; De La Torre RM; Abu-Shahin FI
J Oncol Pharm Pract; 2023 Oct; 29(7):1757-1761. PubMed ID: 37282559
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait.
Rizzo A; Ricci AD; Brandi G
Immunotherapy; 2021 Jun; 13(8):637-644. PubMed ID: 33820447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
